SCHEMBL4519931

SCHEMBL4519931

CCOc1nc(N)nc2ccc(-c3ccc(F)cc3Cl)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PDE2A O00408 2/20 0.36
PDE10A Q9Y233 2/20 0.36
PDE7A Q13946 1/20 0.36
HSP90AA1 P07900 3/20 0.36
HSP90AB1 P08238 3/20 0.36
MPO P05164 2/20 0.36
MAP4K4 O95819 1/20 0.35
DHFR P00374 2/20 0.34
PTPN1 P18031 1/20 0.34
CLK1 P49759 1/20 0.34
KCNH2 Q12809 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
PDE6D O43924 1/20 0.33
PDE6A P16499 1/20 0.33
PDE6G P18545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523975 0.89 MAPT (0.37) MAPTKDM4ETDP1MPOMAP4K4
SCHEMBL4525891 0.88 TLR8 (0.40) MAPTKDM4ETDP1HSP90AA1HSP90AB1
SCHEMBL4524543 0.88 MAPT (0.55) MAPTKDM4ETDP1GAAL3MBTL1
SCHEMBL4530939 0.87 HSP90AA1 (0.35) MAPTKDM4ETDP1PDE2AHSP90AA1
SCHEMBL4527421 0.85 MAPT (0.40) MAPTKDM4ETDP1GAAL3MBTL1
SCHEMBL4522776 0.84 L3MBTL1 (0.54) MAPTKDM4ETDP1GAAL3MBTL1
SCHEMBL4534037 0.84 AMY1A (0.38) HSP90AA1HSP90AB1DHFR
SCHEMBL3760895 0.83 MPO (0.40) MAPTKDM4ETDP1HSP90AA1HSP90AB1
SCHEMBL11911418 0.82 KDM4E (0.46) MAPTKDM4ETDP1GAAL3MBTL1
SCHEMBL4122428 0.82 MPO (0.39) MAPTKDM4EMPOMAP4K4DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 US claimed
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C GILEAD SCIENCES, INC. (US) 2009-05-21 US claimed
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 US disclosed
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 US disclosed
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C GILEAD SCIENCES, INC. (US) 2009-05-21 US disclosed
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C GILEAD SCIENCES, INC. (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C DPYD, TYMP, PNPO MAPT 2859/4885KDM4E 3685/4885TDP1 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.